Drug pricing always comes with political noise, particularly when US elections are concerned. Over the last year, the share prices of pharmaceutical and biotech companies on both sides of the Atlantic have continually swung on the tweets and proclamations of politicians.
In this special podcast, IC companies writer Megan Boxall speaks with industry insiders and cuts through the controversy and policy rumblings, to assess whether there are still good reasons to view pharma and biotech companies as worthwhile investments.
Produced by Alex Newman and Dominic Toms, with music from Blue Dot Sessions; news clips courtesy of Fox. To listen to more Boardroom Talk podcasts, plus our weekly Companies & Markets Show, Personal Finance Show and standalone podcasts, head to acast.com/investorschronicle
